Insight into the metabolic shifts in Graves' hyperthyroidism: a study of acylcarnitine and lipid profiles
European Thyroid Journal · 2025
DOI: 10.1530/etj-25-0004 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Thyroid Journal, 2025. Verfasst von Mikael Thomassen Neset und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Haukeland University Hospital, Bergen, Norway. Hauptthemen laut MEDLINE: Carnitine, Graves Disease, Lipid Metabolism, Lipids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Graves' disease increases metabolism and leads to net lipid degradation. Circulating acylcarnitines reflect lipid metabolism and the state of fatty acid oxidation in individuals. The aim of this study was to explore the lipid and acylcarnitine profiles in patients with Graves' disease.
Methods
Seven lipids/apolipoproteins and 23 acylcarnitines were analysed in 100 newly diagnosed Graves' disease patients and validated in another 51 patients. Both groups were age- and sex-matched with healthy subjects.
Results
The hyperthyroid Graves' disease patients (n = 88) from the main cohort (78 females, median age 42 (17–67) years) had significantly (P < 0.05) higher levels of medium- and long-chain acylcarnitines, and lower levels of short-chain acylcarnitines, compared with healthy subjects. Factor analysis showed that medium- and long-chain acylcarnitines explained most of the differences between the two groups. Serum levels of the five lipids/apolipoproteins were significantly lower in the hyperthyroid Graves' disease patients compared with healthy subjects. Patients (n = 21) treated with antithyroid drugs for 6 weeks had acylcarnitine levels closer to healthy subjects, compared with 79 treatment-naïve hyperthyroid patients. The main findings were confirmed in the validation group.
Conclusion
Increased levels of medium- and long-chain acylcarnitines in patients with newly diagnosed Graves' disease may reflect accelerated catabolism. Lower levels of short-chain acylcarnitines point to Graves' disease being a catabolic condition, with a shift in energy source from carbohydrates to fat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Haukeland University Hospital, Bergen, Norway.
- Department of Clinical Medicine, University of Bergen, Bergen, Norway.
- Bevital A/S, Laboratoriebygget, Bergen, Norway.
- Department of Medicine, Haukeland University Hospital, Bergen, Norway.
- Department of Clinical Science and K.G. Jebsen Center for Autoimmune Diseases, University of Bergen, Bergen, Norway.
- Department of Medicine, Stavanger University Hospital, Stavanger, Norway.
ORCID-Profile: Hans Olav Ueland
Zitieren
APA
Neset, M. T., Ulvik, A., Løvås, K., Laupsa-Borge, J., Breivik, L. E., Stokland, A. M., Nedrebø, B. G., Rødahl, E., Husebye, E., Ueland, G. Å., & Ueland, H. O. (2025). Insight into the metabolic shifts in Graves' hyperthyroidism: a study of acylcarnitine and lipid profiles. European Thyroid Journal. https://doi.org/10.1530/etj-25-0004
Vancouver
Neset MT, Ulvik A, Løvås K, Laupsa-Borge J, Breivik LE, Stokland AM, et al. Insight into the metabolic shifts in Graves' hyperthyroidism: a study of acylcarnitine and lipid profiles. European Thyroid Journal. 2025. doi:10.1530/etj-25-0004
BibTeX
@article{Neset2025,
author = {Neset, Mikael Thomassen and Ulvik, Arve and Løvås, Kristian and Laupsa-Borge, Johnny and Breivik, Lars Ertesvåg and Stokland, Ann-Elin Meling and Nedrebø, Bjørn Gunnar and Rødahl, Eyvind and Husebye, Eystein and Ueland, Grethe Åstrøm and Ueland, Hans Olav},
title = {Insight into the metabolic shifts in Graves' hyperthyroidism: a study of acylcarnitine and lipid profiles},
journal = {European Thyroid Journal},
year = {2025},
doi = {10.1530/etj-25-0004}
}
EUVIMED